

Date Filed: August 27, 2020

Filed On Behalf Of:

Novartis Pharmaceuticals Corporation

By:

Nicholas N. Kallas
nkallas@Venable.com
(212) 218-2243

UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

BIOCON PHARMA LIMITED,
Petitioner,

v.

NOVARTIS PHARMACEUTICALS CORPORATION,
Patent Owner.

Case IPR2020-01263
Patent 8,101,659

**PATENT OWNER'S MANDATORY NOTICES
UNDER 37 C.F.R. § 42.8(a)(2)**

REAL PARTY-IN-INTEREST PURSUANT TO 37 C.F.R. § 42.8(b)(1)

Novartis Pharmaceuticals Corporation (“Novartis”) owns U.S. Patent No. 8,101,659 (“the ’659 Patent”) and is a wholly-owned subsidiary of Novartis AG. Novartis is the real party-in-interest in IPR2020-01263.

RELATED MATTERS PURSUANT TO 37 C.F.R. § 42.8(b)(2)

The ’659 Patent has been or is at issue in the following judicial proceedings:

(1) *In Re: Entresto (Sacubitril/Valsartan) Patent Litig.*, No. 20-md-2930-LPS; (2) *Novartis Pharm. Corp. v. Alkem Labs. Ltd., et al.*, No. 19-cv-1979-LPS (D. Del.); (3) *Novartis Pharm. Corp. v. Alembic Pharm. Ltd., et al.*, No. 19-cv-2021-LPS (D. Del.); (4) *Novartis Pharm. Corp. v. Dr. Reddy’s Labs., Inc., et al.*, No. 19-cv-2053-LPS (D. Del.); (5) *Novartis Pharm. Corp. v. Alembic Pharm. Ltd., et al.*, No. 20-cv-74-LPS (D. Del.); (6) *Novartis Pharm. Corp. v. Lupin Atlantis Holdings, S.A., et al.*, No. 20-cv-415-LPS (D. Del.); (7); *Novartis Pharm. Corp. v. Mylan Pharm. Inc., et al.*, No. 20-cv-445-LPS (D. Del.); (8) *Novartis Pharm. Corp. v. Mylan Pharm. Inc. et al.*, No. 19-cv-201-IMK (N.D.W. Va.); and (9) *Novartis Pharm. Corp. v. Macleods Pharm. Ltd., et al.*, No. 19-cv-19345 (D.N.J.) (dismissed).

IDENTIFICATION OF LEAD AND BACK-UP COUNSEL PURSUANT TO 37 C.F.R. §§ 42.8(b)(3) and 42.10(a)

Novartis designates Nicholas N. Kallas (Reg. No. 31,530) as lead counsel and Christina Schwarz (Reg. No. 78,484) as back-up counsel.

A power of attorney from Novartis is being submitted with this Notice.

SERVICE INFORMATION PURSUANT TO 37 C.F.R. § 42.8(b)(4)

Novartis may be served electronically using the following e-mail address:

nkallas@Venable.com

Novartis may be served by postal mailing, hand-delivery, telephone or facsimile as follows:

Nicholas N. Kallas
Venable LLP
1290 Avenue of the Americas
New York, NY 10104
Telephone: (212) 218-2243
Facsimile: (212) 218-2200

Respectfully submitted,

Dated: August 27, 2020

/ Nicholas N. Kallas /
Nicholas N. Kallas
Registration No. 31,530

CERTIFICATE OF SERVICE

I certify that a copy of Patent Owner's Mandatory Notices Under 37 C.F.R. § 42.8(a)(2) was served on August 27, 2020 by causing it to be sent by email to counsel for Petitioner at the following email addresses:

Christopher Ferenc (christopher.ferenc@katten.com)

Brian Sodikoff (brian.sodikoff@katten.com)

Dated: August 27, 2020

/ Nicholas N. Kallas /
Nicholas N. Kallas
Registration No. 31,530